Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046776 | 0.85 | KDM4E (0.46) | PTGDR2AKR1B1KDM4E | |
| SCHEMBL5041882 | 0.82 | PTGDR2 (0.48) | PTGDR2AKR1B1KDM4EKMO | |
| SCHEMBL11999972 | 0.81 | KDM4E (0.56) | KDM4E | |
| SCHEMBL2793648 | 0.80 | MAT2A (0.54) | PTGDR2AKR1B1KMO | |
| SCHEMBL2798572 | 0.77 | MAT2A (0.36) | PTGDR2AKR1B1KMORHEB | |
| SCHEMBL8046411 | 0.77 | MAT2A (0.52) | PTGDR2AKR1B1KMOAKR1A1AKR1B10 | |
| SCHEMBL21027234 | 0.77 | GLA (0.74) | PTGDR2AKR1B1KDM4EKMOAKR1A1 | |
| SCHEMBL21027254 | 0.75 | PTGDR2 (0.57) | PTGDR2AKR1B1KMOAKR1A1AKR1B10 | |
| SCHEMBL18180179 | 0.74 | APEX1 (0.62) | PTGDR2AKR1B1KDM4EKMOAKR1A1 | |
| SCHEMBL16176365 | 0.74 | KDM4E (0.65) | KDM4EKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | PTGDR2 4185/4885AKR1B1 4243/4885KDM4E 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.